The diagnosis and management of monogenic diabetes in children and adolescents

Oscar Rubio-Cabezasa, Andrew T Hattersleyb, Pål R Njølstadc,d, Wojciech Mlynarskie, Sian Ellardb, Neil Whitef, Dung Vu Chig and Maria E Craigh,i aDepartment of Paediatric Endocrinology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain; bInstitute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, UK; cDepartment of Clinical Science, University of Bergen, Bergen, Norway; dDepartment of Pediatrics, Haukeland University Hospital, Bergen, Norway; eDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland; fDivision of Pediatric Endocrinology and Metabolism, Department of Pediatrics, Washington University School of Medicine, St Louis Children’s Hospital, St. Louis, MO, USA; gDepartment of Pediatric Endocrinology, National Hospital for Pediatrics, Hanoi, Vietnam; hThe Children’s Hospital at Westmead and Discipline of Pediatrics and Child Health, University of Sydney, Sydney, Australia and iSchool of Women’s and Children’s Health, University of New South Wales, Sydney, Australia

[1]  C. Acerini,et al.  Management of cystic fibrosis‐related diabetes in children and adolescents , 2014, Pediatric diabetes.

[2]  T. Hansen,et al.  Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the Young—Type 2 and Type 3 , 2014, Diabetes.

[3]  M. Borowiec,et al.  Population‐based estimates for double diabetes amongst people with glucokinase monogenic diabetes, GCK‐MODY , 2014, Diabetic medicine : a journal of the British Diabetic Association.

[4]  T. Hansen,et al.  Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial , 2014, Diabetes Care.

[5]  K. Raile,et al.  Meglitinide Analogues in Adolescent Patients With HNF1A-MODY (MODY 3) , 2014, Pediatrics.

[6]  M. Skopkova,et al.  De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed , 2014, Diabetologia.

[7]  S. Bens,et al.  Clinical utility gene card for: Transient Neonatal Diabetes Mellitus, 6q24-related , 2014, European Journal of Human Genetics.

[8]  R. Steeds,et al.  Modification of severe insulin resistant diabetes in response to lifestyle changes in Alström syndrome. , 2014, European journal of medical genetics.

[9]  T. Hansen,et al.  Evaluation of a target region capture sequencing platform using monogenic diabetes as a study-model , 2014, BMC Genetics.

[10]  B. Shields,et al.  Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. , 2014, JAMA.

[11]  P. Froguel,et al.  Highly Sensitive Diagnosis of 43 Monogenic Forms of Diabetes or Obesity Through One-Step PCR-Based Enrichment in Combination With Next-Generation Sequencing , 2014, Diabetes Care.

[12]  A. Hattersley,et al.  Analysis of Transcription Factors Key for Mouse Pancreatic Development Establishes NKX2-2 and MNX1 Mutations as Causes of Neonatal Diabetes in Man , 2014, Cell metabolism.

[13]  M. Borowiec,et al.  Delayed Recognition of Wolfram Syndrome Frequently Misdiagnosed as Type 1 Diabetes with Early Chronic Complications , 2014, Experimental and Clinical Endocrinology & Diabetes (Barth).

[14]  S. Gygi,et al.  Carboxyl-Ester Lipase Maturity-Onset Diabetes of the Young Is Associated With Development of Pancreatic Cysts and Upregulated MAPK Signaling in Secretin-Stimulated Duodenal Fluid , 2013, Diabetes.

[15]  Aaron N. Winn,et al.  Cost-Effectiveness of MODY Genetic Testing: Translating Genomic Advances Into Practical Health Applications , 2013, Diabetes Care.

[16]  T. Chatila,et al.  Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. , 2013, Current opinion in pediatrics.

[17]  B. Shields,et al.  The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotype , 2013, Journal of Medical Genetics.

[18]  Anna Murray,et al.  Recessive mutations in a distal PTF1A enhancer cause isolated pancreatic agenesis , 2013, Nature Genetics.

[19]  R. Scharfmann,et al.  Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study [corrected]. , 2013, The lancet. Diabetes & endocrinology.

[20]  B. Shields,et al.  Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia , 2013, Diabetologia.

[21]  V. Parker,et al.  Genetics in endocrinology: genetic forms of severe insulin resistance: what endocrinologists should know. , 2013, European journal of endocrinology.

[22]  S. Ellard,et al.  Diabetes Mellitus in Neonates and Infants: Genetic Heterogeneity, Clinical Approach to Diagnosis, and Therapeutic Options , 2013, Hormone Research in Paediatrics.

[23]  Olivier Poch,et al.  Exome sequencing of Bardet–Biedl syndrome patient identifies a null mutation in the BBSome subunit BBIP1 (BBS18) , 2013, Journal of Medical Genetics.

[24]  Richard Sinnott,et al.  EURO-WABB: an EU rare diseases registry for Wolfram syndrome, Alström syndrome and Bardet-Biedl syndrome , 2013, BMC Pediatrics.

[25]  A. Molven,et al.  Exocrine pancreatic function in hepatocyte nuclear factor 1β‐maturity‐onset diabetes of the young (HNF1B‐MODY) is only moderately reduced: compensatory hypersecretion from a hypoplastic pancreas , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[26]  Stefan Johansson,et al.  SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. , 2013, American journal of human genetics.

[27]  M. Weedon,et al.  Improved genetic testing for monogenic diabetes using targeted next-generation sequencing , 2013, Diabetologia.

[28]  B. Shields,et al.  Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies , 2013, PloS one.

[29]  A. Hattersley,et al.  Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. , 2013, The Journal of clinical endocrinology and metabolism.

[30]  M. Weedon,et al.  An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy , 2013, Nature Genetics.

[31]  T. Orchard,et al.  Current clinical status, glucose control, and complication rates of children and youth with type 1 diabetes in Rwanda , 2013, Pediatric diabetes.

[32]  R. Scharfmann,et al.  Transcription factor gene MNX1 is a novel cause of permanent neonatal diabetes in a consanguineous family. , 2013, Diabetes & metabolism.

[33]  A. Molven,et al.  Prevalence of monogenic diabetes in the population-based Norwegian Childhood Diabetes Registry , 2013, Diabetologia.

[34]  F. Ashcroft,et al.  Switching to Sulphonylureas in Children With iDEND Syndrome Caused by KCNJ11 Mutations Results in Improved Cerebellar Perfusion , 2013, Diabetes Care.

[35]  V. Nunes,et al.  Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype , 2013, Genetics in Medicine.

[36]  A. Hattersley,et al.  Clinical presentation of 6q24 transient neonatal diabetes mellitus (6q24 TNDM) and genotype–phenotype correlation in an international cohort of patients , 2013, Diabetologia.

[37]  E. Mercuri,et al.  Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226‐232 mutation , 2012, Pediatric diabetes.

[38]  J. Gleeson,et al.  A Homozygous IER3IP1 Mutation Causes Microcephaly With Simplified Gyral Pattern, Epilepsy, and Permanent Neonatal Diabetes Syndrome (MEDS) , 2012, American journal of medical genetics. Part A.

[39]  A. Hattersley,et al.  Permanent neonatal diabetes: different aetiology in Arabs compared to Europeans , 2012, Archives of Disease in Childhood.

[40]  C. Stanley,et al.  Novel presentations of congenital hyperinsulinism due to mutations in the MODY genes: HNF1A and HNF4A. , 2012, The Journal of clinical endocrinology and metabolism.

[41]  M. Borowiec,et al.  Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign , 2012, Diabetologia.

[42]  A. Hattersley,et al.  KATP channel mutations in infants with permanent diabetes diagnosed after 6 months of life , 2012, Pediatric diabetes.

[43]  J. Aerts,et al.  Exome Sequencing and Genetic Testing for MODY , 2012, PloS one.

[44]  S. Wiegand,et al.  Diabetes mellitus in children and adolescents with genetic syndromes. , 2012, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[45]  C. Quittner,et al.  Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. , 2012, The Journal of clinical endocrinology and metabolism.

[46]  P. Taschner,et al.  In search of triallelism in Bardet–Biedl syndrome , 2012, European Journal of Human Genetics.

[47]  A. Hattersley,et al.  GATA6 haploinsufficiency causes pancreatic agenesis in humans , 2011, Nature Genetics.

[48]  S. Wiegand,et al.  Reclassification of diabetes type in pediatric patients initially classified as type 2 diabetes mellitus: 15 years follow-up using routine data from the German/Austrian DPV database. , 2011, Diabetes research and clinical practice.

[49]  G. Bell,et al.  MODY: history, genetics, pathophysiology, and clinical decision making. , 2011, Diabetes care.

[50]  K. Rahmouni,et al.  Molecular basis of the obesity associated with Bardet–Biedl syndrome , 2011, Trends in Endocrinology & Metabolism.

[51]  E. Cummings,et al.  Presentation and course of diabetes in children and adolescents with Alstrom syndrome , 2011, Pediatric diabetes.

[52]  A. Hattersley,et al.  Permanent Neonatal Diabetes and Enteric Anendocrinosis Associated With Biallelic Mutations in NEUROG3 , 2011, Diabetes.

[53]  F. Cerutti,et al.  Permanent diabetes during the first year of life: multiple gene screening in 54 patients , 2011, Diabetologia.

[54]  Aaron N. Winn,et al.  The Cost-Effectiveness of Personalized Genetic Medicine , 2011, Diabetes Care.

[55]  R. Ravazzolo,et al.  Genetic investigation in an Italian child with an unusual association of atrial septal defect, attributable to a new familial GATA4 gene mutation, and neonatal diabetes due to pancreatic agenesis , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[56]  F. Ashcroft,et al.  SYMPOSIUM REVIEW: The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet , 2010, The Journal of physiology.

[57]  J. Lalau Lactic Acidosis Induced by Metformin , 2010, Drug safety.

[58]  L. Philipson,et al.  Neonatal diabetes mellitus: A model for personalized medicine , 2010, Trends in Endocrinology & Metabolism.

[59]  F. Ashcroft,et al.  Muscle Dysfunction Caused by a KATP Channel Mutation in Neonatal Diabetes Is Neuronal in Origin , 2010, Science.

[60]  Sian Ellard,et al.  Homozygous Mutations in NEUROD1 Are Responsible for a Novel Syndrome of Permanent Neonatal Diabetes and Neurological Abnormalities , 2010, Diabetes.

[61]  B. Shields,et al.  Maturity-onset diabetes of the young (MODY): how many cases are we missing? , 2010, Diabetologia.

[62]  S. Ellard,et al.  Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations , 2010, European journal of endocrinology.

[63]  J. Skupień,et al.  Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. , 2010, Diabetes technology & therapeutics.

[64]  D. Dunger,et al.  Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. , 2010, The Journal of clinical endocrinology and metabolism.

[65]  B. Shields,et al.  Increased all‐cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[66]  A. Hattersley,et al.  Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis , 2010, Proceedings of the National Academy of Sciences.

[67]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[68]  K. Dewar,et al.  Rfx6 Directs Islet Formation and Insulin Production in Mice and Humans , 2009, Nature.

[69]  Ó. Rubio-Cabezas Diagnosing monogenic diabetes: common misinterpretations of genetic findings , 2009, Pediatric diabetes.

[70]  J. Hahn,et al.  Compound heterozygosity for mutations in PAX6 in a patient with complex brain anomaly, neonatal diabetes mellitus, and microophthalmia , 2009, American journal of medical genetics. Part A.

[71]  A. Hattersley,et al.  Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families. , 2009, The Journal of clinical endocrinology and metabolism.

[72]  J. Argente,et al.  Testing for monogenic diabetes among children and adolescents with antibody‐negative clinically defined Type 1 diabetes , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[73]  A. Moran,et al.  Management of cystic fibrosis‐related diabetes in children and adolescents , 2009, Pediatric diabetes.

[74]  H. Gin,et al.  The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. , 2009, The Journal of clinical endocrinology and metabolism.

[75]  E. Mahone,et al.  Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15‐yr‐old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM , 2009, Pediatric diabetes.

[76]  D. Horn,et al.  Expanded clinical spectrum in hepatocyte nuclear factor 1b-maturity-onset diabetes of the young. , 2009, The Journal of clinical endocrinology and metabolism.

[77]  G. d’Annunzio,et al.  Maturity-Onset Diabetes of the Young in Children With Incidental Hyperglycemia: , 2009, Diabetes Care.

[78]  A. Hattersley,et al.  Tooth Discoloration in Patients With Neonatal Diabetes After Transfer Onto Glibenclamide , 2009, Diabetes Care.

[79]  B. Shields,et al.  A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin‐treated patients , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[80]  F. Meschi,et al.  Insulin Gene Mutations as Cause of Diabetes in Children Negative for Five Type 1 Diabetes Autoantibodies , 2009, Diabetes Care.

[81]  A. Hattersley,et al.  Clinical Heterogeneity in Patients With FOXP3 Mutations Presenting With Permanent Neonatal Diabetes , 2009, Diabetes Care.

[82]  P. Ruszniewski,et al.  The natural history of hereditary pancreatitis: a national series , 2008, Gut.

[83]  A. Hattersley,et al.  Hypomethylation of multiple imprinted loci in individuals with transient neonatal diabetes is associated with mutations in ZFP57 , 2008, Nature Genetics.

[84]  A. Molven,et al.  Lack of pancreatic body and tail in HNF1B mutation carriers , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[85]  T. Hansen,et al.  Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. , 2008, The Journal of clinical investigation.

[86]  A. Hattersley,et al.  Persistent Hyperinsulinemic Hypoglycemia and Maturity-onset Diabetes of the Young Due to Heterozygous Hnf4a Mutations , 2022 .

[87]  P. Yong,et al.  Use of Sirolimus in IPEX and IPEX-Like Children , 2008, Journal of Clinical Immunology.

[88]  Geir Joner,et al.  Mutations in the Insulin Gene Can Cause MODY and Autoantibody-Negative Type 1 Diabetes , 2008, Diabetes.

[89]  R. Scharfmann,et al.  Heterozygous Missense Mutations in the Insulin Gene Are Linked to Permanent Diabetes Appearing in the Neonatal Period or in Early Infancy , 2008, Diabetes.

[90]  F. Cadario,et al.  The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. , 2008, The Journal of clinical endocrinology and metabolism.

[91]  A. Hattersley,et al.  Clinical implications of a molecular genetic classification of monogenic β-cell diabetes , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[92]  S. Ellard,et al.  Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young , 2008, Diabetologia.

[93]  C. Bellanné-Chantelot,et al.  The Type and the Position of HNF1A Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3 , 2008, Diabetes.

[94]  A. Hattersley,et al.  Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. , 2008, Diabetes.

[95]  D. Eizirik,et al.  The role for endoplasmic reticulum stress in diabetes mellitus. , 2008, Endocrine reviews.

[96]  F. Crispim,et al.  Sulfonylrea Treatment in Permanent Neonatal Diabetes Due to G53D Mutation in the KCNJ11 Gene , 2007, Diabetes Care.

[97]  F. Ashcroft,et al.  Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11 , 2007, Nature Clinical Practice Neurology.

[98]  M. Zhang,et al.  A homozygous mutation in a novel zinc-finger protein, ERIS, is responsible for Wolfram syndrome 2. , 2007, American journal of human genetics.

[99]  A. Hattersley,et al.  Insulin gene mutations as a cause of permanent neonatal diabetes , 2007, Proceedings of the National Academy of Sciences.

[100]  F. Ashcroft,et al.  Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. , 2007, American journal of human genetics.

[101]  G. Sebag,et al.  Metabolic Correction Induced by Leptin Replacement Treatment in Young Children With Berardinelli-Seip Congenital Lipoatrophy , 2007, Pediatrics.

[102]  A. Hattersley,et al.  Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. , 2007, The Journal of clinical endocrinology and metabolism.

[103]  A. Hattersley,et al.  Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene , 2007, PLoS medicine.

[104]  P. Beales,et al.  Bardet–Biedl syndrome: beyond the cilium , 2007, Pediatric Nephrology.

[105]  A. Molven,et al.  Pancreatic Lipomatosis Is a Structural Marker in Nondiabetic Children With Mutations in Carboxyl-Ester Lipase , 2007, Diabetes.

[106]  S. Ellard,et al.  Hepatocyte nuclear factor‐1 beta mutations cause neonatal diabetes and intrauterine growth retardation: support for a critical role of HNF‐1β in human pancreatic development , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[107]  A. Hattersley,et al.  Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene , 2006, Diabetologia.

[108]  R. Scharfmann,et al.  Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. , 2006, The New England journal of medicine.

[109]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.

[110]  A. Hattersley,et al.  Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. , 2006, Human molecular genetics.

[111]  R. Siebert,et al.  A maternal hypomethylation syndrome presenting as transient neonatal diabetes mellitus , 2006, Human Genetics.

[112]  P. Bingley,et al.  HLA Genotyping Supports a Nonautoimmune Etiology in Patients Diagnosed With Diabetes Under the Age of 6 Months , 2006, Diabetes.

[113]  F. Ashcroft,et al.  A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. , 2006, Human molecular genetics.

[114]  C. Julier,et al.  Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism , 2006, Nature Genetics.

[115]  A. Hattersley,et al.  KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features , 2006, European Journal of Human Genetics.

[116]  A. Hattersley,et al.  Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype , 2006, Diabetologia.

[117]  T. Hansen,et al.  Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents , 2006, European Journal of Pediatrics.

[118]  P. Massin,et al.  Kearns Sayre syndrome: an unusual form of mitochondrial diabetes. , 2006, Diabetes & metabolism.

[119]  V. Nunes,et al.  Wolfram/DIDMOAD syndrome, a heterogenic and molecularly complex neurodegenerative disease. , 2006, Pediatric endocrinology reviews : PER.

[120]  L. Groop,et al.  Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. , 2006, Diabetes care.

[121]  M. Jadoul,et al.  Large genomic rearrangements in the hepatocyte nuclear factor-1beta (TCF2) gene are the most frequent cause of maturity-onset diabetes of the young type 5. , 2005, Diabetes.

[122]  F. Ashcroft,et al.  Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. , 2005, Diabetes.

[123]  H. Ochs,et al.  Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). , 2005, The Journal of pediatrics.

[124]  F. Ashcroft ATP-sensitive potassium channelopathies: focus on insulin secretion. , 2005, The Journal of clinical investigation.

[125]  A. Hattersley,et al.  β-Cell Dysfunction, Insulin Sensitivity, and Glycosuria Precede Diabetes in Hepatocyte Nuclear Factor-1α Mutation Carriers , 2005 .

[126]  F. Matschinsky Glucokinase, glucose homeostasis, and diabetes mellitus , 2005, Current diabetes reports.

[127]  A. Hattersley,et al.  Mutations in hepatocyte nuclear factor-1β and their related phenotypes , 2005, Journal of Medical Genetics.

[128]  T. Hansen,et al.  Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4α mutations in a large European collection , 2005, Diabetologia.

[129]  A. Hattersley,et al.  High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. , 2005, Diabetes care.

[130]  A. Hattersley,et al.  Mutations in PTF1A cause pancreatic and cerebellar agenesis , 2004, Nature Genetics.

[131]  A. Hattersley,et al.  Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1beta. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[132]  A. Hattersley,et al.  Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. , 2004, Diabetes.

[133]  A. Hattersley,et al.  Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. , 2004, Diabetes.

[134]  G. Rutter,et al.  Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM. , 2004, The Journal of clinical investigation.

[135]  G. Lathrop,et al.  Wolcott-Rallison Syndrome: clinical, genetic, and functional study of EIF2AK3 mutations and suggestion of genetic heterogeneity. , 2004, Diabetes.

[136]  Simeon I. Taylor,et al.  Clinical Course of Genetic Diseases of the Insulin Receptor (Type A and Rabson-Mendenhall Syndromes): A 30-Year Prospective , 2004, Medicine.

[137]  M. Polak,et al.  An assessment of pancreatic endocrine function and insulin sensitivity in patients with transient neonatal diabetes in remission , 2004, Archives of Disease in Childhood - Fetal and Neonatal Edition.

[138]  T. Nakahata,et al.  Neonatal diabetes mellitus and neonatal polycystic, dysplastic kidneys: Phenotypically discordant recurrence of a mutation in the hepatocyte nuclear factor-1beta gene due to germline mosaicism. , 2004, The Journal of clinical endocrinology and metabolism.

[139]  A. Hattersley,et al.  Contrasting Diabetes Phenotypes Associated With Hepatocyte Nuclear Factor-1α and -1β Mutations , 2004 .

[140]  F. Ashcroft,et al.  Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. , 2004, The New England journal of medicine.

[141]  Christine Bellann-Chantelot,et al.  Clinical Spectrum Associated with Hepatocyte Nuclear Factor-1 Mutations , 2004, Annals of Internal Medicine.

[142]  H. Gin,et al.  Heterogeneity of diabetes phenotype in patients with 3243 bp mutation of mitochondrial DNA (Maternally Inherited Diabetes and Deafness or MIDD). , 2004, Diabetes & metabolism.

[143]  A. Garg Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.

[144]  G. Nijpels,et al.  Mitochondrial diabetes: molecular mechanisms and clinical presentation. , 2004, Diabetes.

[145]  A. Molven,et al.  Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. , 2003, Diabetes.

[146]  A. Hattersley,et al.  Genetic cause of hyperglycaemia and response to treatment in diabetes , 2003, The Lancet.

[147]  A. Hattersley,et al.  Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[148]  S. O’Rahilly,et al.  Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. , 2003, The Journal of clinical endocrinology and metabolism.

[149]  P. Bingley,et al.  Identifying hepatic nuclear factor 1alpha mutations in children and young adults with a clinical diagnosis of type 1 diabetes. , 2003, Diabetes care.

[150]  J. Shield,et al.  Transient neonatal diabetes, a disorder of imprinting , 2002, Journal of medical genetics.

[151]  M. Martinetti,et al.  Permanent diabetes mellitus in the first year of life , 2002, Diabetologia.

[152]  H. Yoo,et al.  Identification of a novel mutation in the GLUT2 gene in a patient with Fanconi-Bickel syndrome presenting with neonatal diabetes mellitus and galactosaemia , 2002, European Journal of Pediatrics.

[153]  David I. Wilson,et al.  Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome , 2002, Nature Genetics.

[154]  T. Hansen,et al.  The genetic abnormality in the beta cell determines the response to an oral glucose load , 2002, Diabetologia.

[155]  G I Bell,et al.  Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. , 2001, The New England journal of medicine.

[156]  Bethan E. Hoskins,et al.  Triallelic Inheritance in Bardet-Biedl Syndrome, a Mendelian Recessive Disorder , 2001, Science.

[157]  E. Bonifacio,et al.  Risk of type 1 diabetes development in children with incidental hyperglycemia: A multicenter Italian study. , 2001, Diabetes Care.

[158]  A. Molven,et al.  Neonatal diabetes mellitus due to complete glucokinase deficiency. , 2001, The New England journal of medicine.

[159]  F. Khanim,et al.  WFS1/wolframin mutations, Wolfram syndrome, and associated diseases , 2001, Human mutation.

[160]  A. Franzese,et al.  MODY 2 presenting as neonatal hyperglycaemia: a need to reshape the definition of “neonatal diabetes”? , 2000, Diabetologia.

[161]  G. Lathrop,et al.  EIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndrome , 2000, Nature Genetics.

[162]  J. Barber,et al.  Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. , 2000, Diabetes.

[163]  R. Siebert,et al.  An imprinted locus associated with transient neonatal diabetes mellitus. , 2000, Human molecular genetics.

[164]  A. M. Møller,et al.  Mutations in the hepatocyte nuclear factor-1α gene in Caucasian families originally classified as having Type I diabetes , 1998, Diabetologia.

[165]  P. Behn,et al.  A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome) , 1998, Nature Genetics.

[166]  R. Tattersall,et al.  Maturity‐onset diabetes of the young: a clinical history , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[167]  T. Hansen,et al.  Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3) , 1996, Nature.

[168]  A. Hattersley,et al.  Altered Insulin Secretory Responses to Glucose in Diabetic and Nondiabetic Subjects With Mutations in the Diabetes Susceptibility Gene MODY3 on Chromosome 12 , 1996, Diabetes.

[169]  T. Barrett,et al.  Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome , 1995, The Lancet.

[170]  M. B. Brown,et al.  Administration of Sulfonylureas Can Increase Glucose-Induced Insulin Secretion for Decades in Patients With Maturity-Onset Diabetes of the Young , 1993, Diabetes Care.

[171]  M. Stoffel,et al.  Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus , 1992, Nature.

[172]  I. Nonaka,et al.  A mutation in the tRNALeu(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies , 1990, Nature.

[173]  H. Mandel,et al.  Thiamine-dependent beriberi in the "thiamine-responsive anemia syndrome". , 1984, The New England journal of medicine.

[174]  A. Arbor,et al.  A Difference Between the Inheritance of Classical Juvenile-onset and Maturity-onset Type Diabetes of Young People , 1975, Diabetes.

[175]  R. Tattersall Mild familial diabetes with dominant inheritance. , 1974, The Quarterly journal of medicine.

[176]  Stephen O’Riordana,et al.  Insulin mutation screening in 1 , 044 patients with diabetes : mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood , 2008 .

[177]  S. Davies,et al.  Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. , 2007, Blood.

[178]  A. Molven,et al.  Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction , 2006, Nature Genetics.

[179]  C. Bellanné-Chantelot,et al.  Renal phenotypes related to hepatocyte nuclear factor-1beta (TCF2) mutations in a pediatric cohort. , 2006, Journal of the American Society of Nephrology : JASN.

[180]  J. Girard Hormonal Regulation of Fetal Growth , 2006 .

[181]  R. Gitzelmann,et al.  Pearson bone marrow-pancreas syndrome with insulin-dependent diabetes, progressive renal tubulopathy, organic aciduria and elevated fetal haemoglobin caused by deletion and duplication of mitochondrial DNA , 2005, European Journal of Pediatrics.

[182]  A. Hattersley,et al.  Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. , 2005, Diabetes care.

[183]  A. Hattersley,et al.  Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1alpha and -1beta mutations. , 2004, Diabetes care.

[184]  G. Nijpels,et al.  Molecular mechanisms and clinical presentation , 2004 .

[185]  J. Casanova,et al.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy , 2001, Nature Genetics.

[186]  H. Ochs,et al.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.

[187]  L. Groop,et al.  Chronic diabetic complications in patients with MODY3 diabetes , 1998, Diabetologia.

[188]  William L. Clarke,et al.  Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence , 1997, Nature Genetics.

[189]  P. Froguel,et al.  Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families , 1997, Diabetologia.

[190]  G. Bell,et al.  Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. , 1997, Nature genetics.

[191]  M. Stoffel,et al.  Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1) , 1996, Nature.

[192]  L. Nilsson,et al.  Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree. , 1959, Acta psychiatrica et neurologica Scandinavica. Supplementum.